Clinical trial · Interventional
Comparative Evaluation of MRI and MDCT for the Detection of Metastic Pulmonary Nodules
NCT00751920CI-TRIAL-00020413terminatedPhase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): The sponsor-investigator relocated to a different institution and was not able to continue the study.
Summary
Brief summary (as posted)
The purpose of this study is to apply the techniques of dynamic MRI imaging enhancement to research participants with one or more pulmonary nodule to determine if meaningful information about the nature of the nodule can be obtained. This data will then be compared with follow up information about nodule growth or histology obtained by biopsy or surgical resection.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Metastatic Pulmonary Nodules | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Enhanced MRI Scan | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- 1
- interventionNames
- Procedure: Enhanced MRI Scan
Primary outcomes (1)
- measure
- MRI sensitivity for the detection of pulmonary nodule(s) greater than 3mm in size (diameter) compared to CT
- timeFrame
- One hour
Secondary outcomes (1)
- measure
- How accurate MRI is at distinguishing between benign and malignant pulmonary nodules.
- timeFrame
- One hour
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 2 Years
- Maximum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients between 2-18 years of age * Patients who present themselves to the Department of Diagnostic Imaging at the Hospital for Sick Children for CT of the thorax * Patients undergoing a CT of the thorax for detection of lung metastases following diagnosis of a solid tumor or suspected solid tumor * Patients who present themselves for initial diagnosis or at follow up CT for progression * Able to give informed consent (parents or patients) Exclusion Criteria: * Usual exclusion criteria for MRI (e.g. pacemaker, ocular metal, claustrophobia) * Have any known allergy to one or more of the ingredients in the study contrast agents; have a history of hypersensitivity to any metals or chelates of gadolinium; have a history of allergies or bronchial asthma; use beta blockers, have cardiovascular disease; or have anaphylactic reactions * Have moderate-to-severe renal impairment (defined as having a GFR/ eGFR \< 60 mL/min) * Have sickle cell anemia * MRI of the chest requiring sedation or general anesthesia * Known pregnancy or breast feeding * Renal failure * Patient uncooperative during a MRI without sedation or anesthesia (unless already receiving this for MRI of another body region) * Children under the age of 2 will not be eligible for intravenous contrast
References
Publications (0)
Data not yet available
No reference posted for this study.